Astellas launches Xospata
Astellas Pharma is offering Xospata (gilteritinib) for the treatment of adult patients who have relapsed or treatment resistant acute myeloid leukemia with a FLT3 mutation detected by an FDA-approved test.
Acute myeloid leukemia is a cancer that impacts the blood and bone marrow, and its incidence increases with age.
Xospata, an oral monotherapy, is the first and only FLT3-targeting agent approved by the FDA for the treatment of relapsed or refractory FLT3 mutation positive (FLT3mut+) acute myeloid leukemia, according to the company.
"Astellas aims to pursue cutting-edge science that provides value to patients," Astellas' senior vice president of oncology business unit Mark Reisenauer said. "Xospata is an excellent example of how we are continuing to advance on this promise to patients."
Gilteritinib was discovered through a research collaboration with Kotobuki Pharmaceutical. Astellas has exclusive global rights to develop, manufacture and commercialize gilteritinib.
Acute myeloid leukemia is a cancer that impacts the blood and bone marrow, and its incidence increases with age.
Xospata, an oral monotherapy, is the first and only FLT3-targeting agent approved by the FDA for the treatment of relapsed or refractory FLT3 mutation positive (FLT3mut+) acute myeloid leukemia, according to the company.
"Astellas aims to pursue cutting-edge science that provides value to patients," Astellas' senior vice president of oncology business unit Mark Reisenauer said. "Xospata is an excellent example of how we are continuing to advance on this promise to patients."
Gilteritinib was discovered through a research collaboration with Kotobuki Pharmaceutical. Astellas has exclusive global rights to develop, manufacture and commercialize gilteritinib.